Format

Send to

Choose Destination
Dig Dis Sci. 2018 Apr;63(4):920-933. doi: 10.1007/s10620-018-4944-4. Epub 2018 Feb 8.

Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.

Author information

1
Clinical Proteomics Unit, IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy.
2
Pancreas Unit, Department of Digestive System, Sant'Orsola-Malpighi Hospital, Via Massarenti, 9, 40138, Bologna, Italy. raffaele.pezzilli@aosp.bo.it.
3
Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy.
4
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

Abstract

BACKGROUND:

There are a limited number of studies investigating the type of serum proteins capable of differentiating intraductal papillary mucinous neoplasms from benign or malignant diseases of the pancreas.

AIMS:

To select proteins able to differentiate intraductal papillary mucinous neoplasms from benign and malignant pancreatic disease using semiquantitative proteomics.

METHODS:

Serum samples were obtained from 74 patients (19 with type II intraductal papillary mucinous neoplasms, 8 with type I/III intraductal papillary mucinous neoplasms, 24 with chronic pancreatitis, 23 with pancreatic ductal adenocarcinomas) and 21 healthy subjects. Small proteins and peptides were assayed by matrix-assisted laser desorption/ionization for the detection of differentially abundant species possibly related to tumor onset. Serum pancreatic amylase, lipase, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA 19-9) were also assayed.

RESULTS:

Twenty-six of 84 peaks detected were dysregulated (7 more abundant and 19 less abundant in the type II intraductal papillary mucinous neoplasms, p < 0.05). Of the differentially abundant peaks, 17 were commonly dysregulated (3 peaks more abundant and 13 less abundant in type II intraductal papillary mucinous neoplasms, and one at  m/z = 9961 at variance), indicating a protein fingerprint shared by types I/III and type II intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinomas.

CONCLUSIONS:

These results suggest that our approach can be used to differentiate type II intraductal papillary mucinous neoplasms from type I/III neoplasms, and type II intraductal papillary mucinous neoplasms from pancreatic ductal adenocarcinomas.

KEYWORDS:

Biomarkers; Cystic; Matrix-assisted laser desorption/ionization; Neoplasms; Pancreatic cancer; Pancreatitis

PMID:
29417328
DOI:
10.1007/s10620-018-4944-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center